statistiche ricercatore

Continente	#
NA - Nord America	518
AS - Asia	482
EU - Europa	232
SA - Sud America	80
AF - Africa	28
Continente sconosciuto - Info sul continente non disponibili	1
Totale	1.341

Nazione	#
US - Stati Uniti d'America	485
SG - Singapore	166
CN - Cina	102
IT - Italia	80
VN - Vietnam	79
BR - Brasile	51
DE - Germania	48
HK - Hong Kong	41
IN - India	32
CA - Canada	20
FI - Finlandia	20
JP - Giappone	17
ZA - Sudafrica	17
GB - Regno Unito	16
FR - Francia	13
ID - Indonesia	12
PL - Polonia	9
AR - Argentina	8
MX - Messico	8
BD - Bangladesh	7
RU - Federazione Russa	7
PE - Perù	6
UA - Ucraina	6
CH - Svizzera	5
CZ - Repubblica Ceca	5
NL - Olanda	5
TR - Turchia	5
EC - Ecuador	4
VE - Venezuela	4
DZ - Algeria	3
ES - Italia	3
IL - Israele	3
IQ - Iraq	3
KE - Kenya	3
PT - Portogallo	3
SE - Svezia	3
CL - Cile	2
CO - Colombia	2
GA - Gabon	2
JM - Giamaica	2
KR - Corea	2
NP - Nepal	2
PA - Panama	2
PH - Filippine	2
AL - Albania	1
AT - Austria	1
AZ - Azerbaigian	1
BE - Belgio	1
BJ - Benin	1
BO - Bolivia	1
CR - Costa Rica	1
ET - Etiopia	1
GR - Grecia	1
IE - Irlanda	1
JO - Giordania	1
KG - Kirghizistan	1
KH - Cambogia	1
LA - Repubblica Popolare Democratica del Laos	1
LT - Lituania	1
LU - Lussemburgo	1
LV - Lettonia	1
MY - Malesia	1
OM - Oman	1
PK - Pakistan	1
PY - Paraguay	1
RO - Romania	1
TN - Tunisia	1
TW - Taiwan	1
UY - Uruguay	1
XK - ???statistics.table.value.countryCode.XK???	1
Totale	1.341

Nome	#
An engineered factor X variant as a novel by-passing agent for hemophilia	157
OTC intron 4 variations mediate pathogenic splicing patterns caused by the c.386G>A mutation in humans and spfash mice, and govern susceptibility to RNA-based therapies	148
Counteracting the Common Shwachman-Diamond Syndrome-Causing SBDS c.258+2T>C Mutation by RNA Therapeutics and Base/Prime Editing	146
A factor X variant with engineered activation peptide as innovative by-passing agent for haemophilia	128
Addressing pathogenic splicing mutations through RNA therapeutics and DNA editing approaches	121
Deep molecular mechanisms of F8 exon 19 variants and translational approaches in Hemophilia A	118
Rescue of a FVIII splicing variant with engineered U1snRNAs	95
A 5’ SPLICE-SITE MUTATION CAUSING MUCOLIPIDOSIS TYPE III CAN BE EFFICIENTLY RESCUED BY U1 SNRNA-BASED THERAPY	81
Rescue of an F8 splicing variant (c.1752+5 G>C) with engineered U1snRNAs	78
Rescue of a panel of Hemophilia A-causing 5’ss splicing mutations by unique Exon-specific U1snRNA variants	78
Rescue of a hemophilia A-causing FVIII splicing variant via engineered U1SNRNAS	77
Rescue of a panel of splicing mutations causing hemophilia A by engineered U1snRNAs	73
RESCUE OF A PANEL OF SPLICING MUTATIONS CAUSING HEMOPHILIA A BY ENGINEERED U1-SNRNAS	50
Prime editing of the common Familial Dysautonomia-causing c.2204+6T>C splicing mutation	16
Totale	1.366

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	15	0	0	1	0	1	3	0	2	2	0	0	6
2022/2023	36	2	2	1	1	3	2	12	2	4	0	6	1
2023/2024	60	5	6	6	2	2	14	6	4	3	1	1	10
2024/2025	329	12	9	21	12	26	36	7	21	50	37	43	55
2025/2026	926	120	50	75	97	121	65	100	49	85	106	52	6
Totale													1.366

SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara